ArticleScientific reports2025
Synergetic effect of a DSP4-induced locus coeruleus lesion and systemic LPS exacerbates substantia nigra dopaminergic neuron loss.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson’s disease (PD) involves progressive degeneration of dopaminergic neurons in the substantia nigra (SN) and noradrenergic neurons in the locus coeruleus (LC). Noradrenaline (NA), produced by LC neurons, has anti-inflammatory properties and seems to support SN dopaminergic neuron survival. This study used a dual-hit approach to examine how noradrenergic loss affects SN vulnerability to induced inflammation in Sprague-Dawley rats. LC denervation was produced with [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine] (DSP4), a selective LC noradrenergic neurotoxin, and a systemic inflammatory challenge was induced with a subthreshold dose of lipopolysaccharide (LPS). Behavioral assessments were performed, and neuronal populations were quantified by unbiased stereology. DSP4 or LPS alone reduced tyrosine hydroxylase-positive neurons in both LC and SN, with the DSP4-induced SN loss linked to NA depletion. DSP4 and LPS co-treatment produced greater dopaminergic degeneration in the substantia nigra than either treatment alone, suggesting an additive effect. Furthermore, immunoanalytical analysis using ELISA demonstrated altered cytokine levels in both SN and LC. Taken together, the results support a dual-hit theory, in which additive insults act to push the system toward a tipping point, beyond which SN dopaminergic cell loss becomes extensive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.